Latigo Biotherapeutics, Inc.

Latigo Biotherapeutics, Inc. (LTGO) priced its initial public offering on Aug 7, 2026 at $18.00 per share, within its $16.00–$18.00 range, raising $345.6M, and listed on Nasdaq Global Select. At the IPO price its market capitalization was about $1.14B. Goldman Sachs was lead-left underwriter, joined by Jefferies, Leerink Partners and Guggenheim. Cooley advised the company and Latham & Watkins advised the underwriters.

Latigo Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company developing non-opioid pain medicines designed to stop pain transmission without the risk of addiction, for acute and chronic pain.

Status

IPO

Ticker

LTGO

Exchange

Nasdaq Global Select

Priced

Aug 7, 2026

IPO price

$18.00

Price range

$16.00–$18.00

Raised

$345.6M

Market cap at IPO price

$1.14B

First filed

Jul 17, 2026

Underwriters

Goldman Sachs, Jefferies, Leerink Partners and Guggenheim

Company counsel

Cooley

Underwriters' counsel

Latham & Watkins

Sector

Biotech & pharma

Country / state

CA

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.